InSilico Medicine Launches Hong Kong IPO

MT Newswires Live

Dec 18

InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.

The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.

The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.

The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.

InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.

Morgan Stanley, China International Capital Corp., GF Securities (Hong Kong), BNP Paribas Securities (Asia), Sinolink Securities (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592928946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592928946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592928946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592928946","market":"us","top_or_hot":-1,"title":"InSilico Medicine Launches Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.</p><p>The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.</p><p>The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.</p><p>The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.</p><p>InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.</p><p>Morgan Stanley, China International Capital Corp., <a href=\"https://laohu8.com/S/GFSEF\">GF Securities</a> (Hong Kong), BNP Paribas Securities (Asia), <a href=\"https://laohu8.com/S/600109\">Sinolink Securities</a> (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InSilico Medicine Launches Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInSilico Medicine Launches Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-18 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.</p><p>The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.</p><p>The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.</p><p>The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.</p><p>InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.</p><p>Morgan Stanley, China International Capital Corp., <a href=\"https://laohu8.com/S/GFSEF\">GF Securities</a> (Hong Kong), BNP Paribas Securities (Asia), <a href=\"https://laohu8.com/S/600109\">Sinolink Securities</a> (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592928946","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592928946","pubTimestamp":1766023317,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InSilico Medicine  launched its initial public offering in Hong Kong to raise HK$2.28 billion.The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.Morgan Stanley, China International Capital Corp., GF Securities , BNP Paribas Securities , Sinolink Securities , and BOCI Asia are the joint bookrunners of the IPO.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"InSilico Medicine启动香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":0.9},"content_text":"InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.Morgan Stanley, China International Capital Corp., GF Securities (Hong Kong), BNP Paribas Securities (Asia), Sinolink Securities (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}